HomeCompareNEMKY vs PFE

NEMKY vs PFE: Dividend Comparison 2026

NEMKY yields 0.81% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NEMKY wins by $573.2K in total portfolio value
10 years
NEMKY
NEMKY
● Live price
0.81%
Share price
$15.00
Annual div
$0.12
5Y div CAGR
88.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$622.8K
Annual income
$435,333.65
Full NEMKY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NEMKY vs PFE

📍 NEMKY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNEMKYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NEMKY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NEMKY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEMKY
Annual income on $10K today (after 15% tax)
$68.56/yr
After 10yr DRIP, annual income (after tax)
$370,033.60/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, NEMKY beats the other by $347,713.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEMKY + PFE for your $10,000?

NEMKY: 50%PFE: 50%
100% PFE50/50100% NEMKY
Portfolio after 10yr
$336.2K
Annual income
$230,796.19/yr
Blended yield
68.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NEMKY
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
5.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEMKY buys
0
PFE buys
0
No recent congressional trades found for NEMKY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNEMKYPFE
Forward yield0.81%6.13%
Annual dividend / share$0.12$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR88.5%13.2%
Portfolio after 10y$622.8K$49.6K
Annual income after 10y$435,333.65$26,258.71
Total dividends collected$585.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: NEMKY vs PFE ($10,000, DRIP)

YearNEMKY PortfolioNEMKY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,852$152.03$9,153$693.39+$1.7KNEMKY
2$11,902$290.65$8,593$849.25+$3.3KNEMKY
3$13,297$561.59$8,336$1,066.78+$5.0KNEMKY
4$15,333$1,105.28$8,437$1,384.80+$6.9KNEMKY
5$18,652$2,245.31$9,013$1,875.40+$9.6KNEMKY
6$24,769$4,811.63$10,306$2,680.72+$14.5KNEMKY
7$37,759$11,256.63$12,820$4,101.38+$24.9KNEMKY
8$70,634$30,231.02$17,673$6,826.70+$53.0KNEMKY
9$175,203$99,624.49$27,543$12,591.86+$147.7KNEMKY
10$622,800$435,333.65$49,560$26,258.71+$573.2KNEMKY

NEMKY vs PFE: Complete Analysis 2026

NEMKYStock

Nemetschek SE provides software solutions for architecture, engineering, construction, media, and entertainment markets in Germany, rest of Europe, the Americas, the Asia Pacific, and internationally. It operates through four segments: Design, Build, Manage, and Media & Entertainment. The Design segment offers software solutions primarily under the Allplan, Graphisoft, Solibri, Precast, Vectorworks, SCIA, dRofus, Data Design System, Frilo, and RISA brands for architects, designers, engineers, structural engineers, specialist planners, and landscape designers, as well as developers and general contractors. This segment provides building information modeling (BIM) solutions for computer aided design and computer aided engineering in 2D and 3D building design and imaging. The Build segment offers integrated complete 5D BIM solutions primarily under the Bluebeam brand that support bidding and awarding, invoicing, budgeting, scheduling, and cost calculation; and commercial enterprise resource planning solutions. This segment serves construction companies, developers, building supplies, and general contractors, as well as planning offices, architects, and civil engineers. The Manage segment provides commercial property management services under the Crem brand; and modular and integrated software solutions for property, facility, and workplace management under the Spacewell brand for facility and property managers, banks, and insurance and property companies; and intelligent smart building platform. The Media & Entertainment segment offers software solutions under the Maxon name for rendering 3D modeling, animation, and visual effects that are used in film, television, advertising, and video game productions, as well as in medicine, product design, and infographics. The company was founded in 1963 and is headquartered in Munich, Germany.

Full NEMKY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NEMKY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEMKY vs SCHDNEMKY vs JEPINEMKY vs ONEMKY vs KONEMKY vs MAINNEMKY vs JNJNEMKY vs MRKNEMKY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.